| 11.38 -0.44 (-3.72%) | 08-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.29 | 1-year : | 16.69 |
| Resists | First : | 12.23 | Second : | 14.29 |
| Pivot price | 11.38  |
|||
| Supports | First : | 10.98 | Second : | 10.21 |
| MAs | MA(5) : | 11.63 |
MA(20) : | 11.2 |
| MA(100) : | 11.43 |
MA(250) : | 12.04 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 71.1 |
D(3) : | 74.5 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 16.97 | Low : | 8.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INKT ] has closed above bottom band by 49.4%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.81 - 11.88 | 11.88 - 11.95 |
| Low: | 10.89 - 10.97 | 10.97 - 11.03 |
| Close: | 11.27 - 11.39 | 11.39 - 11.49 |
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Thu, 13 Aug 2026
MiNK Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Thu, 13 Aug 2026
Initial ventilated patients treated in MiNK's trial were alive at Day 28 - Stock Titan
Thu, 13 Aug 2026
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research Symposium - Slideshow - Seeking Alpha
Thu, 06 Aug 2026
New agenT-797 lung-injury data due from MiNK Aug. 13 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 59.2 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 94 (K) |
| Shares Short P.Month | 112 (K) |
| EPS | -2.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -129.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -4.81 |
| PEG Ratio | 0 |
| Price to Book value | -4.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|